Avelumab First-Line Maintenance Treatment for Advanced Urothelial Carcinoma: Insights From Real-World Evidence in More Than 5000 Patients - European Medical Journal

This site is intended for healthcare professionals

This content is for healthcare professionals outside of the USA

Continue

Avelumab First-Line Maintenance Treatment for Advanced Urothelial Carcinoma: Insights From Real-World Evidence in More Than 5000 Patients

Oncology
Urology

The publication of this interactive article was funded by Merck

Support: The publication of this interactive article was funded by Merck KGaA, Darmstadt, Germany. EMD Serono is the healthcare business of Merck KGaA, Darmstadt, Germany in the United States and Canada. This medical activity was sponsored by Merck KGaA, Darmstadt, Germany (CrossRef Funder ID: 10.13039/100009945).

Rate this content's potential impact on patient outcomes

Average rating / 5. Vote count:

No votes so far! Be the first to rate this content.

We’ve noticed you’re accessing
from North/South America.